Platelets News and Research

RSS

Study supports flexible blood transfusion options in emergency trauma care

Giving whole blood or the component parts of blood are equally effective options for paramedics and emergency medical technicians to use in treating patients with severe, traumatic bleeding before arriving at the hospital, according to a large, nationwide trial directed by University of Pittsburgh and UPMC clinicians and scientists.

19 May 2026

Scientists identify specialized cells that trigger bone marrow cavity growth

Bone marrow is the spongy tissue located within the hollow center of bones, serving as the primary site for the continuous production of red blood cells, platelets, and white blood cells.

28 Apr 2026

Geo-mapping to identify high-need areas for trauma blood delivery

Research shows geomapping can pinpoint trauma hotspots, optimizing prehospital blood supply deployment and potentially saving lives in urgent care scenarios.

21 Apr 2026

CAR T therapy induces remission in multiple autoimmune diseases

For the first time, scientists have used a cutting-edge cell therapy called CAR-T to treat a patient with three different life-threatening autoimmune diseases that had resisted years of treatment.

9 Apr 2026

Injectable microgels reduce surgical bleeding risk in infants

Biomedical researchers have designed an injectable microgel to help reduce bleeding in infants who require surgical care. In an animal model, the engineered microgel reduced bleeding by at least 50%.

3 Apr 2026

ASH releases updated recommendations for severe acquired aplastic anemia care

The American Society of Hematology (ASH) released guidelines on the diagnosis and management of severe acquired aplastic anemia, a rare and life-threatening bone marrow failure disorder.

1 Apr 2026

Collaboration advances EMA601 as potential first-in-class stroke therapy

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody EMA601.

30 Mar 2026

Romiplostim prevents chemotherapy-induced thrombocytopenia in phase 3 trial

Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication romiplostim can effectively prevent chemotherapy from destroying platelet-producing bone marrow cells, a common complication known as chemotherapy-induced thrombocytopenia.

12 Mar 2026

Highlighting the global "care gap" in life-threatening injuries

A new international study published in The Lancet eClinicalMedicine has mapped global blood transfusion practices for life-threatening abdominal injuries, highlighting significant variation in care worldwide and opportunities for health systems to learn from one another.

4 Mar 2026

Researchers find new way to halt leukemia stem cell growth

In a new study published in Nature Communications, a research team at the University of Oslo have examined how cancer cells develop in the bone marrow and whether it might be possible to stop them.

18 Feb 2026

ASH releases new guidelines for treating leukemia in adolescents and young adults

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease in this population.

12 Feb 2026

Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis

A global research collaboration of scientists from McMaster University (Canada), Flinders University (Australia) and Universitätsmedizin Greifswald (Germany) uncovered why a small number of people developed dangerous blood clots after either receiving certain COVID‑19 vaccines or experiencing a natural adenovirus infection, and the answer lies in an unexpected case of misdirected targeting by the immune system.

11 Feb 2026

Investigational anti-clotting drug reduces risk of second ischemic stroke without bleeding concerns

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary late-breaking science presentation at the American Stroke Association's International Stroke Conference 2026.

6 Feb 2026

New platform improves prediction of human antibody drug responses

An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how antibody medicines are tested and brought to patients. The

1 Feb 2026

Antiplatelet medications linked to worse outcomes in people hospitalized with a brain bleed

Analysis of hospital registry data found that people who were hospitalized due to bleeding in the brain and who had taken multiple antiplatelet medications, or medications stronger than aspirin, were more likely to die before leaving the hospital compared to those not taking any antiplatelet medication, according to a preliminary study to be presented at the American Stroke Association's International Stroke Conference 2026.

29 Jan 2026

Scientists discover a non-classical platelet mechanism linked to severe infections

Platelets are small, anucleate blood cells that play an essential role in hemostasis. Their primary task is to recognize vascular injury, become activated, and aggregate via their surface receptor integrin αIIbβ3. This leads to the formation of a stable platelet plug that seals the wound and stops bleeding. When this process becomes dysregulated, however, it can result in vessel-occluding clots - so-called thromboses - which may cause myocardial infarction or stroke.

23 Jan 2026

Non-monetary incentives boost blood donation without harming safety

Offering non-monetary incentives such as free access to outpatient consultations to frequent blood donors is linked to an increase in donations without compromising blood safety, finds a study from China published by The BMJ today.

21 Jan 2026

Exercise-triggered mitochondrial transfer offers hope for stroke and dementia

Physical rehabilitation and symptom management still remain the mainstay of treatment for stroke, as clot removal or dissolution is effective only within a narrow time frame after the stroke.

21 Jan 2026

HonorHealth patient first in Arizona to receive new investigational treatment for ischemic stroke

A stroke patient at HonorHealth Research Institute is the first in Arizona to receive a new investigational treatment that targets platelets - rather than traditional clotting proteins - to help reopen blocked blood vessels in the brain.

20 Jan 2026

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

9 Dec 2025